Redcare Pharmacy (DE:RDC)
XETRA:RDC
Want to see DE:RDC full AI Analyst Report?
RDC Stock Chart & Stats
€50.50
€4.70(3.90%)
At close: 4:00 PM EST
€50.50
€4.70(3.90%)
Day’s Range― - ―
52-Week Range€30.20 - €114.00
Previous CloseN/A
Volume73.26K
Average Volume (3M)132.76K
Market Cap
€1.01B
Enterprise Value€1.15B
Total Cash (Recent Filing)€135.00M
Total Debt (Recent Filing)€354.80M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Jul 29, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding20,578,390
10 Day Avg. Volume128,637
30 Day Avg. Volume132,758
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€74.21Price Target Upside46.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€3.35B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~21.6% revenue growth signals expanding market share and customer adoption across its online pharmacy platforms. Over 2-6 months this revenue momentum underpins scale benefits, supports supplier leverage and marketing efficiency, and provides a base to improve unit economics.
Improving EBITDAPositive and improving EBITDA indicates operating leverage is emerging as top-line scales. Durable cost structure gains in fulfillment and marketing can translate to sustainable cash operating profits, creating a clearer path toward converting EBITDA into net profitability over coming quarters.
Manageable LeverageDebt below equity with an improving debt-to-equity ratio (~0.79) reduces near-term financial strain and preserves borrowing flexibility. This balance-sheet headroom supports continued investment in growth and execution without immediate solvency pressure, assuming losses moderate.
Bears Say
Persistent Net LossesOngoing negative net income erodes retained earnings and constrains the company’s ability to self-fund growth. Even with improving EBITDA, failure to convert to net profits means continued dependence on external capital and sustained pressure on equity compounding over months.
Deeply Negative Free Cash FlowDeeply negative trailing‑12‑month free cash flow indicates cash conversion issues and rising working capital or investment needs. This elevates refinancing risk and limits nimbleness for strategic initiatives, making the business dependent on continued access to external financing.
Gross Margin ErosionA declining gross margin signals pricing pressure or adverse mix shifts toward lower‑margin front‑shop products. Margin compression reduces the payoff from revenue growth and makes it harder to absorb fixed costs, slowing progress from positive EBITDA to sustainable net profitability.
Redcare Pharmacy News
RDC FAQ
What was Redcare Pharmacy’s price range in the past 12 months?
Redcare Pharmacy lowest stock price was €30.20 and its highest was €114.00 in the past 12 months.
What is Redcare Pharmacy’s market cap?
Redcare Pharmacy’s market cap is €1.01B.
When is Redcare Pharmacy’s upcoming earnings report date?
Redcare Pharmacy’s upcoming earnings report date is Jul 29, 2026 which is in 50 days.
How were Redcare Pharmacy’s earnings last quarter?
Redcare Pharmacy released its earnings results on May 06, 2026. The company reported -€0.503 earnings per share for the quarter, missing the consensus estimate of -€0.458 by -€0.045.
Is Redcare Pharmacy overvalued?
According to Wall Street analysts Redcare Pharmacy’s price is currently Undervalued.
Does Redcare Pharmacy pay dividends?
Redcare Pharmacy does not currently pay dividends.
What is Redcare Pharmacy’s EPS estimate?
Redcare Pharmacy’s EPS estimate is -0.3.
How many shares outstanding does Redcare Pharmacy have?
Redcare Pharmacy has 20,578,390 shares outstanding.
What happened to Redcare Pharmacy’s price movement after its last earnings report?
Redcare Pharmacy reported an EPS of -€0.503 in its last earnings report, missing expectations of -€0.458. Following the earnings report the stock price went down -5.391%.
Which hedge fund is a major shareholder of Redcare Pharmacy?
Currently, no hedge funds are holding shares in DE:RDC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Redcare Pharmacy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€74.21 (46.96% Upside)
€74.21 (46.96% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.98%
12-Months-Change
Fundamentals
Return on Equity
-7.79%
Trailing 12-Months
Asset Growth
15.34%
Trailing 12-Months
Company Description
Redcare Pharmacy
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription medications, over-the-counter drugs, pharmacy-related beauty and personal care items, and nutritional supplements. Established in 2001, the firm, initially known as Shop Apotheke Europe N.V., officially rebranded to Redcare Pharmacy N.V. in June 2023. Its operational headquarters are situated in Sevenum, the Netherlands.
RDC Stock 12 Month Forecast
Average Price Target
€74.21
▲(46.96% Upside)
Technical Analysis
Options Prices
Currently, No data available
---